Neonatal Fc receptor : role and implications in maternal fetal medicine].

During pregnancy, the mother's IgG immunoglobulins cross the -placenta via the neonatal Fc receptor (FcRn), enabling the fetus to acquire passive immunity. In the presence of maternal allo- or auto-antibodies, placental transfer of these pathogenic antibodies mediated by FcRn can cause diseases in the fetus and/or the newborn. FcRn blockade therefore appears to be a therapeutic strategy in these high-risk pregnancies, firstly by reducing IgG recycling, -thereby reducing its concentration in the maternal circulation, and secondly by blocking placental transfer. The promising results of a recent trial testing nipocalimab, a monoclonal antibody targeting FcRn, in very severe erythrocyte alloimmunisation, has opened the way to new targeted therapeutic approaches for perinatal diseases mediated by maternal IgG.

Citation

Émeline Maisonneuve, Alice Panchaud, David Baud, Mathilde Gavillet. Neonatal Fc receptor : role and implications in maternal fetal medicine]. Revue medicale suisse. 2024 Oct 16;20(891):1869-1873

Mesh Tags

Substances

PMID: 39429174

search → result